Holen Sie sich die Stockscreener-App
448.28
0.24%
-1.09
Handel nachbörslich:
445.00
-3.28
-0.73%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$449.37
Offen:
$446.8
24-Stunden-Volumen:
1.67M
Relative Volume:
0.79
Marktkapitalisierung:
$166.59B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
24.65
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
+2.27%
1M Leistung:
-12.78%
6M Leistung:
-23.69%
1J Leistung:
+11.94%
1-Tages-Spanne:
$444.41
$454.45
1-Wochen-Bereich:
$435.27
$455.00
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Did Thermo Fisher’s AI-Focused Investor Day and Clario Deal Just Redefine TMO’s Investment Narrative? - simplywall.st
Thermo Fisher (TMO) director gets 499-share award, 80 withheld for tax - Stock Titan
Director at Thermo Fisher (NYSE: TMO) granted new shares - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share stock award - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share equity grant - Stock Titan
Thermo Fisher (TMO) director receives 499-share stock grant, now holds 2,602 - Stock Titan
Thermo Fisher (TMO) director Tyler Jacks receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) awarded 499 common shares - Stock Titan
Thermo Fisher (TMO) director Ruby R. Chandy receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) receives 499-share stock grant - Stock Titan
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
What Thermo Fisher CEO Said at Investor Day That the Market Is Still Processing - TIKR.com
What Thermo Fisher Scientific (TMO)'s New Gothenburg Lab Expansion Means For Shareholders - Yahoo Finance
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County - PA Department of Community & Economic Development (.gov)
Thermo Fisher Scientific Inc. Balance Sheet – BVL:TMOUS - TradingView
Automated Microbiology Market to Reach USD 13.50 Billion by 2033 - openPR.com
Thermo Fisher Scientific’s SWOT analysis: stock navigates growth amid strategic shifts - Investing.com
High-Throughput Screening (HTS) Market Research Report to 2032 - openPR.com
Thermo Fisher Scientific Announces Quarterly Dividend - The National Law Review
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Declares Consistent Dividend of $0.47 Per Share - GuruFocus
TD Cowen Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating - Moomoo
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day - BioSpace
Press Release: Thermo Fisher Scientific Announces Quarterly Dividend - 富途牛牛
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 a Share, Payable July 15 to Shareholders of Record on June 15 - marketscreener.com
Thermo Fisher Scientific Inc Investor Day Transcript - GuruFocus
Thermo Fisher Scientific Inc Annual Shareholders Meeting Transcript - GuruFocus
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation - PharmiWeb.com
Thermo Fisher (TMO) Showcases Growth Potential at Investor Day - GuruFocus
Thermo Fisher (TMO) Projects Steady Growth with Strategic Focus - GuruFocus
Thermo Fisher Scientific highlights industry leadership, growth outlook and long-term value creation at 2026 Investor Day - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term - Investing.com
Thermo Fisher Expects 7% Annual Organic Revenue Growth Over Long Term - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term By Investing.com - Investing.com Canada
Thermo Fisher Scientific : 2026 Investor Day - marketscreener.com
Thermo Fisher targets a $255B science market as AI reshapes drug discovery - Stock Titan
TMO Technical Indicators, RSI, MACD & Moving Averages - techi.com
Thermo Fisher Scientific Inc. announces Quarterly dividend, payable on July 15, 2026 - marketscreener.com
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here’s What Happened - TIKR.com
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - PR Newswire UK
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics - News-Medical
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - BioSpace
12% Of This Thermo Fisher Scientific Insider's Holdings Were Sold - Moomoo
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with Ne - PharmiWeb.com
Top Companies Driving Innovation In Specimen Bag Zip Closure Solutions - SNS Insider
Life Science Instrumentation Market Forecast Report - GlobeNewswire
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading - Yahoo Finance
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
12,952 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by North Dakota State Investment Board - MarketBeat
Do Wall Street Analysts Like Thermo Fisher Scientific Stock? - Yahoo Finance
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):